Navigation Links
New Study Shows Long-Term Benefits for Patients with Pulmonary Arterial Hypertension
Date:4/24/2009

Results of a recent two-year study show promising long-term survival benefits for patients living with Pulmonary Arterial Hypertension (PAH), a progressive, life-threatening disease in which the small blood vessels in the lungs become scarred and narrowed causing the pressure in the pulmonary arteries to rise to dangerously high levels, putting a major strain on the heart.

Paris, FR (PRWEB) April 24, 2009 -- Results of a recent two-year study show promising long-term survival benefits for patients living with Pulmonary Arterial Hypertension (PAH), a progressive, life-threatening disease in which the small blood vessels in the lungs become scarred and narrowed causing the pressure in the pulmonary arteries to rise to dangerously high levels, putting a major strain on the heart.

During the last decade, there has been an explosion of novel, targeted treatment options, which have shown to increase quality of life and exercise tolerance in individuals living with PAH; however, research of these new treatments has focused mainly on outcomes other than survival in shorter term three-to-12 month studies.

Data will be presented tomorrow (Saturday, April 25) during the morning plenary session (9:15am local time) at the International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting at the Palais des Congres in Paris.

In tomorrow's ISHLT session, Professor Anne Keogh, Senior Transplant Cardiologist, St. Vincent's Hospital, Sydney, Australia, will discuss information specific to a study of longer-term effects of the oral treatment of Ambrisentan (ABS) in patients with PAH.

According to Professor Keogh, ABS doses of 5 mg or 10 mg per day were associated with 87 percent and 94 percent, respectively, two-year survival rates. Only one in five patients required additional drug therapy. Functional parameters and exercise tolerance were improved, and clinical worsening was reduced by ABS.

Discussion during this year's ISHLT meeting presents a unique forum for debating the latest advances in the management of patients with PAH. The annual ISHLT sessions provide the only formal international gathering where pulmonologists, cardiologists and cardiothoracic surgeons meet to share the very latest research and breakthroughs. PAH is a disease that is pertinent to the practices of all of these specialists, so it is of particular interest to ISHLT.

Treatment for PAH:

Ambrisentan, approved for use in patients with PAH, is a selective oral endothelin receptor antagonist, which means it blocks the action of endothelin, a very potent, naturally occurring vasoconstrictor that is capable of causing severe narrowing of the blood vessels. This treatment is intended to improve the symptoms, exercise tolerance and overall survival of PAH patients. Ambrisentan is believed to be associated with a lower risk of liver toxicity and fewer significant drug-to-drug interactions than other approved oral endothelin receptor antagonists.

Without treatment the prognosis for patients with PAH is worse than many cancers, yet until recently there has been no evidence that targeted oral treatments offer significant longer term survival benefits. The results of this two-year study are novel and will increase understanding of the role of such medications in PAH for physicians and patients.

About ISHLT:

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization with more than 2,700 members from over 45 countries dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. For more information, visit www.ishlt.org.

###

Read the full story at http://www.prweb.com/releases/2009/04/prweb2355964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dont Lower Age for Cervical Cancer Test, Study Urges
2. Mayo clinic study finds gene bringing together animal and human research in alcoholism
3. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
4. Mayo Clinic Study Finds Gene Bringing Together Animal and Human Research in Alcoholism
5. Study links arm/hand swelling to number of lymph nodes removed during breast cancer surgery
6. New study argues for CT colonography as primary colon cancer screening test
7. Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study
8. Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
9. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
10. BUSM study finds photographs of UV exposure can impact sunburns in preteens
11. Telesso initiates post-market head-to-head peripheral IV catheter study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Sugar Land, TX (PRWEB) , ... February 12, ... ... the families of southwest Houston and surrounding communities by continuing it’s commitment to ... Fort Bend Family Promise. The organization works closely with area homeless families to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic ... for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ... in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and ...
(Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... the field of long term care. With that, says Patrick Loughney, president of ... in administrative roles in long term care environments. His company, which offers prep ...
(Date:2/12/2016)... ... ... Planet Future is a Final Cut Pro X themed package ... pictures, videos as well as text in an exciting cartoon environment. Planet Future is ... beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media into the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
Breaking Medicine Technology: